Framework for Adoption of Next-Generation Sequencing (NGS) Globally in the Oncology Area
Radical new possibilities of improved treatment of cancer are on offer from an advanced medical technology already demonstrating its significance: next-generation sequencing (NGS). This refined testing provides unprecedentedly precise diagnoses and permits the use of focused and highly personalized...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Healthcare |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9032/11/3/431 |
| _version_ | 1797624559755591680 |
|---|---|
| author | Denis Horgan Yosr Hamdi Jonathan A. Lal Teresia Nyawira Salomé Meyer Dominique Kondji Ngiambudulu M. Francisco Roselle De Guzman Anupriya Paul Branka Bernard Krishna Reddy Nallamalla Woong-Yang Park Vijay Triapthi Ravikant Tripathi Amber Johns Mohan P. Singh Maude E. Phipps France Dube Hadi Mohamad Abu Rasheed Marta Kozaric Joseph A. Pinto Stephen Doral Stefani Maria Eugenia Aponte Rueda Ricardo Fujita Alarcon Hugo A. Barrera-Saldana |
| author_facet | Denis Horgan Yosr Hamdi Jonathan A. Lal Teresia Nyawira Salomé Meyer Dominique Kondji Ngiambudulu M. Francisco Roselle De Guzman Anupriya Paul Branka Bernard Krishna Reddy Nallamalla Woong-Yang Park Vijay Triapthi Ravikant Tripathi Amber Johns Mohan P. Singh Maude E. Phipps France Dube Hadi Mohamad Abu Rasheed Marta Kozaric Joseph A. Pinto Stephen Doral Stefani Maria Eugenia Aponte Rueda Ricardo Fujita Alarcon Hugo A. Barrera-Saldana |
| author_sort | Denis Horgan |
| collection | DOAJ |
| description | Radical new possibilities of improved treatment of cancer are on offer from an advanced medical technology already demonstrating its significance: next-generation sequencing (NGS). This refined testing provides unprecedentedly precise diagnoses and permits the use of focused and highly personalized treatments. However, across regions globally, many cancer patients will continue to be denied the benefits of NGS as long as some of the yawning gaps in its implementation remain unattended. The challenges at the regional and national levels are linked because putting the solutions into effect is highly dependent on cooperation between regional- and national-level cooperation, which could be hindered by shortfalls in interpretation or understanding. The aim of the paper was to define and explore the necessary conditions for NGS and make recommendations for effective implementation based on extensive exchanges with policy makers and stakeholders. As a result, the European Alliance for Personalised Medicine (EAPM) developed a maturity framework structured around demand-side and supply-side issues to enable interested stakeholders in different countries to self-evaluate according to a common matrix. A questionnaire was designed to identify the current status of NGS implementation, and it was submitted to different experts in different institutions globally. This revealed significant variability in the different aspects of NGS uptake. Within different regions globally, to ensure those conditions are right, this can be improved by linking efforts made at the national level, where patients have needs and where care is delivered, and at the global level, where major policy initiatives in the health field are underway or in preparation, many of which offer direct or indirect pathways for building those conditions. In addition, in a period when consensus is still incomplete and catching up is needed at a political level to ensure rational allocation of resources—even within individual countries—to enable the best ways to make the necessary provisions for NGS, a key recommendation is to examine where closer links between national and regional actions could complement, support, and mutually reinforce efforts to improve the situation for patients. |
| first_indexed | 2024-03-11T09:44:08Z |
| format | Article |
| id | doaj.art-9ee4f2ead4ff4c2a910cdb388d84082a |
| institution | Directory Open Access Journal |
| issn | 2227-9032 |
| language | English |
| last_indexed | 2024-03-11T09:44:08Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Healthcare |
| spelling | doaj.art-9ee4f2ead4ff4c2a910cdb388d84082a2023-11-16T16:45:16ZengMDPI AGHealthcare2227-90322023-02-0111343110.3390/healthcare11030431Framework for Adoption of Next-Generation Sequencing (NGS) Globally in the Oncology AreaDenis Horgan0Yosr Hamdi1Jonathan A. Lal2Teresia Nyawira3Salomé Meyer4Dominique Kondji5Ngiambudulu M. Francisco6Roselle De Guzman7Anupriya Paul8Branka Bernard9Krishna Reddy Nallamalla10Woong-Yang Park11Vijay Triapthi12Ravikant Tripathi13Amber Johns14Mohan P. Singh15Maude E. Phipps16France Dube17Hadi Mohamad Abu Rasheed18Marta Kozaric19Joseph A. Pinto20Stephen Doral Stefani21Maria Eugenia Aponte Rueda22Ricardo Fujita Alarcon23Hugo A. Barrera-Saldana24European Alliance for Personalised Medicine, 1040 Brussels, BelgiumLaboratory of Biomedical Genomics and Oncogenetics, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1002, TunisiaDepartment of Molecular and Cellular Engineering, Jacob Institute of Biotechnology and Bioengineering, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj 211007, IndiaNational Commission for Science, Technology and Innovation in Kenya (NACOSTI), Nairobi 00100, KenyaCancer Alliance, Cape Town 7700, South AfricaHealth & Development Communication, Building Capacity for Better Health in Africa, Yaounde P.O. Box 2032, CameroonGrupo de Investigação Microbiana e Imunológica, Instituto Nacional de Investigação em Saúde (National Institute for Health Research), Luanda 3635, AngolaOncology and Pain Management Section, Manila Central University—Filemon D. Tanchoco Medical Foundation Hospital, Caloocan 1400, PhilippinesDepartment of Mathematics and Statistics, Faculty of Science, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj 211007, IndiaEuropean Alliance for Personalised Medicine, 1040 Brussels, BelgiumACCESS Health India, Hyderabad 500086, IndiaSamsung Medical Center, Samsung Genome Institute, Sungkyunkwan University, Seoul 06351, Republic of KoreaDepartment of Molecular and Cellular Engineering, Jacob Institute of Biotechnology and Bioengineering, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj 211007, IndiaDepartment Health Government of India, Ministry of Labor, New Delhi 110001, IndiaCancer Division, Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney 2010, AustraliaCenter of Biotechnology, University of Allahabad, Allahabad 211002, IndiaJeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Subang Jaya 47500, Selangor, MalaysiaPrecision Medicine and Breast Cancer Department, Astra Zeneca, 1800 Concord Pike, Wilmington, DE 19803, USAQatar Cancer Society, Doha 22944, QatarEuropean Alliance for Personalised Medicine, 1040 Brussels, BelgiumCenter for Basic and Translational Research, Auna Ideas, Lima 15036, PeruUNIMED RS, Porto Alegre 90040-180, BrazilVenezuelan Breast Cancer Research and Education Foundation, Caracas 1060, VenezuelaCentro de Genética y Biología Molecular, Universidad de San Martín de Porres, Lima 15024, PeruInnbiogem SC/Vitagenesis SA at National Laboratory for Services of Research, Development, and Innovation for the Pharma and Biotech Industries (LANSEIDI) of CONACyT Vitaxentrum Group, Monterrey 64630, MexicoRadical new possibilities of improved treatment of cancer are on offer from an advanced medical technology already demonstrating its significance: next-generation sequencing (NGS). This refined testing provides unprecedentedly precise diagnoses and permits the use of focused and highly personalized treatments. However, across regions globally, many cancer patients will continue to be denied the benefits of NGS as long as some of the yawning gaps in its implementation remain unattended. The challenges at the regional and national levels are linked because putting the solutions into effect is highly dependent on cooperation between regional- and national-level cooperation, which could be hindered by shortfalls in interpretation or understanding. The aim of the paper was to define and explore the necessary conditions for NGS and make recommendations for effective implementation based on extensive exchanges with policy makers and stakeholders. As a result, the European Alliance for Personalised Medicine (EAPM) developed a maturity framework structured around demand-side and supply-side issues to enable interested stakeholders in different countries to self-evaluate according to a common matrix. A questionnaire was designed to identify the current status of NGS implementation, and it was submitted to different experts in different institutions globally. This revealed significant variability in the different aspects of NGS uptake. Within different regions globally, to ensure those conditions are right, this can be improved by linking efforts made at the national level, where patients have needs and where care is delivered, and at the global level, where major policy initiatives in the health field are underway or in preparation, many of which offer direct or indirect pathways for building those conditions. In addition, in a period when consensus is still incomplete and catching up is needed at a political level to ensure rational allocation of resources—even within individual countries—to enable the best ways to make the necessary provisions for NGS, a key recommendation is to examine where closer links between national and regional actions could complement, support, and mutually reinforce efforts to improve the situation for patients.https://www.mdpi.com/2227-9032/11/3/431next-generation sequencingNGSavailabilitymolecular tumour boardreimbursementsurvey |
| spellingShingle | Denis Horgan Yosr Hamdi Jonathan A. Lal Teresia Nyawira Salomé Meyer Dominique Kondji Ngiambudulu M. Francisco Roselle De Guzman Anupriya Paul Branka Bernard Krishna Reddy Nallamalla Woong-Yang Park Vijay Triapthi Ravikant Tripathi Amber Johns Mohan P. Singh Maude E. Phipps France Dube Hadi Mohamad Abu Rasheed Marta Kozaric Joseph A. Pinto Stephen Doral Stefani Maria Eugenia Aponte Rueda Ricardo Fujita Alarcon Hugo A. Barrera-Saldana Framework for Adoption of Next-Generation Sequencing (NGS) Globally in the Oncology Area Healthcare next-generation sequencing NGS availability molecular tumour board reimbursement survey |
| title | Framework for Adoption of Next-Generation Sequencing (NGS) Globally in the Oncology Area |
| title_full | Framework for Adoption of Next-Generation Sequencing (NGS) Globally in the Oncology Area |
| title_fullStr | Framework for Adoption of Next-Generation Sequencing (NGS) Globally in the Oncology Area |
| title_full_unstemmed | Framework for Adoption of Next-Generation Sequencing (NGS) Globally in the Oncology Area |
| title_short | Framework for Adoption of Next-Generation Sequencing (NGS) Globally in the Oncology Area |
| title_sort | framework for adoption of next generation sequencing ngs globally in the oncology area |
| topic | next-generation sequencing NGS availability molecular tumour board reimbursement survey |
| url | https://www.mdpi.com/2227-9032/11/3/431 |
| work_keys_str_mv | AT denishorgan frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT yosrhamdi frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT jonathanalal frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT teresianyawira frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT salomemeyer frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT dominiquekondji frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT ngiambudulumfrancisco frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT roselledeguzman frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT anupriyapaul frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT brankabernard frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT krishnareddynallamalla frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT woongyangpark frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT vijaytriapthi frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT ravikanttripathi frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT amberjohns frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT mohanpsingh frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT maudeephipps frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT francedube frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT hadimohamadaburasheed frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT martakozaric frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT josephapinto frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT stephendoralstefani frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT mariaeugeniaaponterueda frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT ricardofujitaalarcon frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea AT hugoabarrerasaldana frameworkforadoptionofnextgenerationsequencingngsgloballyintheoncologyarea |